JPH11222457A - Water-solubilized composition of aromatic carboxylic acids, and solubtlify-improved aqueous solution - Google Patents
Water-solubilized composition of aromatic carboxylic acids, and solubtlify-improved aqueous solutionInfo
- Publication number
- JPH11222457A JPH11222457A JP2080098A JP2080098A JPH11222457A JP H11222457 A JPH11222457 A JP H11222457A JP 2080098 A JP2080098 A JP 2080098A JP 2080098 A JP2080098 A JP 2080098A JP H11222457 A JPH11222457 A JP H11222457A
- Authority
- JP
- Japan
- Prior art keywords
- aromatic carboxylic
- water
- carboxylic acids
- chitosan
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】この発明は、例えば医薬品等
として使用されるアスピリン（アセチルサリチル酸）等
の芳香族カルボン酸類の水に対する溶解度を向上化した
芳香族カルボン酸類の水溶性化組成物及び溶解度向上化
水溶液に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for improving the solubility of aromatic carboxylic acids such as aspirin (acetylsalicylic acid) used in pharmaceuticals and the like in water, and to a method for improving the solubility of the same. Aqueous solution.
【０００２】[0002]
【従来の技術】一般的に、解熱剤や鎮痛剤等の医薬品等
として広く使用されているアスピリン（アセチルサリチ
ル酸）、安息香酸、サリチル酸等の芳香族カルボン酸類
は、アルコール、エーテル、油脂類には易溶であるが、
水には溶けにくい疎水性の化合物である。2. Description of the Related Art Generally, aromatic carboxylic acids such as aspirin (acetylsalicylic acid), benzoic acid and salicylic acid, which are widely used as drugs such as antipyretics and analgesics, are readily available in alcohols, ethers and fats and oils. It is soluble,
It is a hydrophobic compound that is hardly soluble in water.
【０００３】そのため、この芳香族カルボン酸類を内用
薬として使用する場合等には、粉末や錠剤の状態で水と
共に服用するようにしている。[0003] Therefore, when the aromatic carboxylic acids are used as an internal medicine, they are taken together with water in the form of powder or tablets.
【０００４】[0004]
【発明が解決しようとする課題】しかしながら、芳香族
カルボン酸類を粉末や錠剤の状態で服用する場合には、
服用しにくいと共に、吸収率が低く、体内滞留時間も短
いという問題点がある。However, when taking aromatic carboxylic acids in powder or tablet form,
It is difficult to take, has a low absorption rate, and has a short residence time in the body.
【０００５】この発明は、以上のような事情や問題点に
鑑みてなされたものであり、芳香族カルボン酸類を内用
薬として使用する場合等における服用の簡便化や吸収率
の増加を図ることができると共に、体内滞留時間が長く
て徐放性を有するように、水に対する溶解度を向上化し
た芳香族カルボン酸類の水溶性化組成物及び溶解度向上
化水溶液を提供することを目的とする。[0005] The present invention has been made in view of the above circumstances and problems, and aims to simplify the administration and increase the absorption rate when using aromatic carboxylic acids as an internal medicine. It is an object of the present invention to provide a water-soluble composition of an aromatic carboxylic acid having improved solubility in water and an aqueous solution having improved solubility so as to have a long residence time in the body and a sustained release property.
【０００６】[0006]
【課題を解決するための手段】上記目的を達成するため
に、請求項１の芳香族カルボン酸類の水溶性化組成物の
手段とするところは、芳香族カルボン酸類に所定量のキ
トサンを添加、混合したことにある。Means for Solving the Problems In order to achieve the above-mentioned object, the means for the water-solubilizing composition of aromatic carboxylic acids according to claim 1 is to add a predetermined amount of chitosan to aromatic carboxylic acids, It is mixed.
【０００７】請求項２の手段とするところは、前記キト
サンの添加量が、前記芳香族カルボン酸類の重量の１．
３倍以下であることにある。According to a second aspect of the present invention, the amount of the chitosan added is 1% of the weight of the aromatic carboxylic acid.
It is three times or less.
【０００８】請求項３の芳香族カルボン酸類の溶解度向
上化水溶液の手段とするところは、水に芳香族カルボン
酸類とキトサンとをそれぞれ所定濃度で溶解させたこと
にある。[0008] The means of the aqueous solution for improving the solubility of aromatic carboxylic acids according to claim 3 is that an aromatic carboxylic acid and chitosan are dissolved in water at predetermined concentrations.
【０００９】請求項４の手段とするところは、前記芳香
族カルボン酸類の濃度が３．２ｇ／ｄＬ以下で、且つ、
前記キトサンの濃度がこの芳香族カルボン酸類の濃度の
１．３倍以下であることにある。According to a fourth aspect of the present invention, the concentration of the aromatic carboxylic acid is not more than 3.2 g / dL, and
The concentration of the chitosan is not more than 1.3 times the concentration of the aromatic carboxylic acids.
【００１０】[0010]
【発明の実施の形態】以下、この発明の実施形態につい
て説明する。なお、第１実施形態では芳香族カルボン酸
類の水溶性化組成物、第２実施形態では芳香族カルボン
酸類の溶解度向上化水溶液についてそれぞれ説明する。Embodiments of the present invention will be described below. In the first embodiment, a water-solubilizing composition of an aromatic carboxylic acid will be described, and in the second embodiment, an aqueous solution of an aromatic carboxylic acid having improved solubility will be described.
【００１１】第１実施形態に係る芳香族カルボン酸類の
水溶性化組成物は、芳香族カルボン酸類に所定量のキト
サンを添加、混合したものである。The water-soluble composition of aromatic carboxylic acids according to the first embodiment is obtained by adding a predetermined amount of chitosan to aromatic carboxylic acids and mixing them.
【００１２】前記芳香族カルボン酸類としては、例え
ば、アスピリン（アセチルサリチル酸）、安息香酸、サ
リチル酸、アントラニル酸（ｏ−アミノ安息香酸）、ｍ
−トルイル酸、ベンジル酸、ｏ−トルイル酸（ｏ−メチ
ル安息香酸）やこれらのナトリウム塩等の塩、あるいは
誘導体等が挙げられる。前記キトサンとしては、脱アセ
チル化度が８０％以上のものが望ましい。The aromatic carboxylic acids include, for example, aspirin (acetylsalicylic acid), benzoic acid, salicylic acid, anthranilic acid (o-aminobenzoic acid), m
-Toluic acid, benzyl acid, o-toluic acid (o-methylbenzoic acid), salts thereof such as sodium salt, and derivatives thereof. The chitosan desirably has a degree of deacetylation of 80% or more.
【００１３】前記水溶性化組成物を調製するには、適宜
の芳香族カルボン酸類の粉末に所定量のキトサンの粉末
を添加し、十分に混合すればよい。この水溶性化組成物
を水に添加して所定時間攪拌すれば、単独では水に対し
てほとんど溶解しなかった芳香族カルボン酸類をより高
濃度で溶解させることができ、その溶解度を向上できる
という利点がある。これは、水溶液中における芳香族カ
ルボン酸類とキトサンの相互作用の寄与によるものと考
えられる。In order to prepare the water-solubilizing composition, a predetermined amount of chitosan powder is added to an appropriate aromatic carboxylic acid powder and mixed well. If this water-solubilizing composition is added to water and stirred for a predetermined time, aromatic carboxylic acids which were hardly dissolved in water alone can be dissolved at a higher concentration, and the solubility can be improved. There are advantages. This is thought to be due to the contribution of the interaction between the aromatic carboxylic acids and chitosan in the aqueous solution.
【００１４】そのため、前記芳香族カルボン酸類を内用
薬として使用する場合等には、前記水溶性化組成物を水
に溶解させれば十分な量の芳香族カルボン酸類が溶解し
ていると共に、水溶液として服用できるので、服用の簡
便化や吸収率の増加を図ることができる。また、水溶液
として服用した場合には、体内滞留時間が長くて徐放性
があるという利点がある。更に、芳香族カルボン酸類と
キトサンとを混合した水溶性化組成物をあらかじめ調製
しておけば、これを必要に応じて水に溶解させるだけで
あるので、便利であるという利点がある。Therefore, when the aromatic carboxylic acids are used as an internal medicine, a sufficient amount of the aromatic carboxylic acids can be dissolved by dissolving the water-solubilizing composition in water. Since it can be taken as an aqueous solution, simplification of taking and an increase in absorptivity can be achieved. In addition, when taken as an aqueous solution, there is the advantage that the residence time in the body is long and sustained release is achieved. Further, if a water-solubilizing composition prepared by mixing an aromatic carboxylic acid and chitosan is prepared in advance, it is convenient to simply dissolve it in water as needed.
【００１５】ここで、前記キトサンの添加量が、前記芳
香族カルボン酸類の重量の１．３倍以下である場合に
は、前記水溶性化組成物が水に溶解し易いという利点が
ある。Here, when the amount of the chitosan added is 1.3 times or less the weight of the aromatic carboxylic acid, there is an advantage that the water-solubilizing composition is easily dissolved in water.
【００１６】第２実施形態に係る芳香族カルボン酸類の
溶解度向上化水溶液は、水に芳香族カルボン酸類とキト
サンとをそれぞれ所定濃度で溶解させたものである。The aqueous solution for improving the solubility of aromatic carboxylic acids according to the second embodiment is obtained by dissolving aromatic carboxylic acids and chitosan at predetermined concentrations in water.
【００１７】この溶解度向上化水溶液を調製するには、
第１実施形態の水溶性化組成物を水に溶解させるか、あ
るいは混合していない芳香族カルボン酸類とキトサンと
を同時に又は別々に水に溶解させればよい。このよう
に、芳香族カルボン酸類に加えてキトサンを溶解させて
いるので、第１実施形態と同様に、より高濃度の芳香族
カルボン酸類が溶解しているという利点がある。そのた
め、この溶解度向上化水溶液をあらかじめ調製しておけ
ば、前記水溶性化組成物等を溶解させる手間を省けると
共に、内用薬等としてそのまますぐに利用できるという
利点がある。To prepare this aqueous solution having improved solubility,
The water-solubilizing composition of the first embodiment may be dissolved in water, or an unmixed aromatic carboxylic acid and chitosan may be dissolved in water simultaneously or separately. As described above, since chitosan is dissolved in addition to the aromatic carboxylic acids, there is an advantage that a higher concentration of the aromatic carboxylic acids is dissolved as in the first embodiment. Therefore, preparing this aqueous solution with improved solubility in advance has the advantage that the time and effort for dissolving the water-solubilizing composition and the like can be omitted and that the composition can be used immediately as an internal medicine or the like.
【００１８】ここで、前記芳香族カルボン酸類の濃度が
３．２ｇ／ｄＬ以下で、且つ、前記キトサンの濃度がこ
の芳香族カルボン酸類の濃度の１．３倍以下である場合
には、芳香族カルボン酸類の溶け残りがほとんど又は全
くないという利点がある。Here, when the concentration of the aromatic carboxylic acid is 3.2 g / dL or less and the concentration of the chitosan is 1.3 times or less the concentration of the aromatic carboxylic acid, There is an advantage that little or no residual carboxylic acid remains.
【００１９】[0019]
【実施例】次に、この発明を実施例により更に詳細に説
明するが、この発明は係る実施例に限定されるものでは
ない。Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
【００２０】〔実施例１〕芳香族カルボン酸類として、
市販のフェノキシ酢酸、ＤＬ−マンデル酸、ｍ−アミノ
安息香酸、ｐ−アミノ安息香酸、無水フタル酸、無水ト
リメリット酸、プロトカテク酸、５−スルホサリチル酸
二水和物、アスピリン（＝アセチルサリチル酸）、安息
香酸、サリチル酸、アントラニル酸（＝ｏ−アミノ安息
香酸）、ｍ−トルイル酸、ベンジル酸、ｏ−トルイル酸
（＝ｏ−メチル安息香酸）、テレフタル酸、イソフタル
酸、１−ナフタレン酢酸（＝α−ナフチル酸）、１−ナ
フトエ酸、チオサリチル酸、ｐ−ニトロ安息香酸、ｐ−
tert−ブチル安息香酸、テレフタル酸ジメチル、及び５
−ヒドロキシイソフタル酸を、それぞれ０．５ｇ／ｄＬ
の割合で所定量の水に添加し、室温（約２５℃）で約１
２時間攪拌した後、溶解性状を観察し、下記の評価基準
に基づいてそれぞれ評価を行った。その結果を表１に示
す。Example 1 As aromatic carboxylic acids,
Commercially available phenoxyacetic acid, DL-mandelic acid, m-aminobenzoic acid, p-aminobenzoic acid, phthalic anhydride, trimellitic anhydride, protocatechuic acid, 5-sulfosalicylic acid dihydrate, aspirin (= acetylsalicylic acid), Benzoic acid, salicylic acid, anthranilic acid (= o-aminobenzoic acid), m-toluic acid, benzylic acid, o-toluic acid (= o-methylbenzoic acid), terephthalic acid, isophthalic acid, 1-naphthaleneacetic acid (= α -Naphthylic acid), 1-naphthoic acid, thiosalicylic acid, p-nitrobenzoic acid, p-
tert-butylbenzoic acid, dimethyl terephthalate, and 5
0.5 g / dL of hydroxyisophthalic acid
At a room temperature (approximately 25 ° C.).
After stirring for 2 hours, the dissolution properties were observed, and each was evaluated based on the following evaluation criteria. Table 1 shows the results.
【００２１】〔評価基準〕 ◎：完全溶解 ○：少量の不溶解分を認める。 △：不溶解分は多いが、粘性がある。 ×：不溶[Evaluation Criteria] 溶解: Completely dissolved ：: A small amount of insoluble matter is recognized. Δ: There are many insoluble components, but they are viscous. ×: Insoluble
【００２２】[0022]
【表１】 [Table 1]
【００２３】また、上記の溶液又は懸濁液にキトサン
（商品名「ＳＫ−１０」，甲陽ケミカル社製，脱アセチ
ル化度：８０％）を０．５ｇ／ｄＬの割合で添加し、室
温（約２５℃）で更に約１２時間攪拌した後、溶解性状
を観察し、上記の評価基準に基づいて評価を行った。そ
の結果も表１に示す。Further, chitosan (trade name “SK-10”, manufactured by Koyo Chemical Co., Ltd., degree of deacetylation: 80%) is added to the above solution or suspension at a rate of 0.5 g / dL, and room temperature ( After stirring at about 25 ° C.) for about 12 hours, the dissolution property was observed and evaluated based on the above evaluation criteria. Table 1 also shows the results.
【００２４】〔実施例２〕芳香族カルボン酸類として市
販のアスピリン（アセチルサリチル酸）を使用し、この
アスピリンと実施例１と同じキトサンとを同時に水に加
え、室温（約２５℃）で約２４時間攪拌した。この操作
をキトサン−アスピリンの比率及び添加量を変えてそれ
ぞれ行い、溶解性状を実施例１と同様にして観察した。
その結果を表２に示す。Example 2 A commercially available aspirin (acetylsalicylic acid) was used as an aromatic carboxylic acid, and this aspirin and the same chitosan as in Example 1 were simultaneously added to water, and the mixture was added at room temperature (about 25 ° C.) for about 24 hours. Stirred. This operation was performed while changing the ratio of chitosan-aspirin and the amount of addition, and the solubility was observed in the same manner as in Example 1.
Table 2 shows the results.
【００２５】[0025]
【表２】 [Table 2]
【００２６】〔実施例３〕実施例２と同じキトサンとア
スピリンとをそれぞれの濃度が１．０ｇ／ｄＬとなるよ
うにして水に溶解させた後、その水溶液をエバポレータ
ーで濃縮乾固し、更に５０℃で一晩乾燥させて、赤外吸
収スペクトルの測定サンプル（サンプルａ）とした。Example 3 The same chitosan and aspirin as in Example 2 were dissolved in water so that the respective concentrations became 1.0 g / dL, and the aqueous solution was concentrated to dryness using an evaporator. It was dried at 50 ° C. overnight to obtain a measurement sample of infrared absorption spectrum (sample a).
【００２７】また、キトサンとアスピリンとを粉体のま
ま１：１の割合でよく混合し、赤外吸収スペクトルの測
定サンプル（サンプルｂ）とした。In addition, chitosan and aspirin were mixed well at a ratio of 1: 1 in powder form to obtain a sample for infrared absorption spectrum measurement (sample b).
【００２８】上記のサンプルａとサンプルｂについて、
赤外吸収スペクトルをそれぞれ測定した（分解：４ｃｍ
-1，アポダイゼーション：Cosine，積算回数：２０
０）。その結果を図１乃至図３に示す。なお、図３は、
サンプルａとサンプルｂの両方のスペクトルを同じチャ
ートに表示したものである。また、図４及び図５に示す
ように、キトサンとアスピリンのそれぞれ単独の赤外吸
収スペクトルも測定した。With respect to the sample a and the sample b,
The infrared absorption spectrum was measured (decomposition: 4 cm
-1 , apodization: Cosine, number of accumulation: 20
0). The results are shown in FIGS. In addition, FIG.
The spectra of both sample a and sample b are displayed on the same chart. In addition, as shown in FIGS. 4 and 5, the infrared absorption spectra of chitosan and aspirin, respectively, were also measured.
【００２９】〔実施例４〕ラット８頭を用い、４頭には
市販のアスピリン（添加量３．２ｇ／ｄＬ）のＣＭＣ
（カルボキシメチルセルロース，添加量３．２ｇ／ｄ
Ｌ）懸濁液を１０ｍｇ／ｋｇの割合で経口投与し（対照
群）、他の４頭には実施例２と同様にして調製したキト
サン−アスピリン水溶液（各添加量は３．２ｇ／ｄＬ）
を１０ｍｇ／ｋｇの割合で経口投与した（試験群）。Example 4 Eight rats were used, and four of them were commercially available aspirin (addition amount: 3.2 g / dL) of CMC.
(Carboxymethylcellulose, added amount 3.2 g / d
L) The suspension was orally administered at a rate of 10 mg / kg (control group), and the other four animals were treated with chitosan-aspirin aqueous solution prepared in the same manner as in Example 2 (each addition amount was 3.2 g / dL).
Was orally administered at a rate of 10 mg / kg (test group).
【００３０】ラットは、実験前日の夜は絶食させ、絶食
の間は生理食塩水を自由に飲ませた。上記の薬物を投与
した後、１、３、６、９時間後にそれぞれ採血し、血漿
中のアスピリンの濃度変化を高速液体クロマトグラフィ
ー（ＨＰＬＣ）により調べた。この間は、絶食絶水させ
た。そして、Ｃmax （最高血漿中濃度）、ＡＵＣ（０〜
９ｈ，吸収されたアスピリン量の比例定数）、ＭＲＴ
（平均体内滞留時間）をそれぞれ測定した。その結果を
表３に示す。なお、Ｔmax （最高血漿中濃度到達時間）
は、各採血時間の測定値から読み取った。The rats were fasted the night before the experiment and had free access to saline during the fasting. Blood was collected at 1, 3, 6, and 9 hours after administration of the above drug, and the change in the concentration of aspirin in plasma was examined by high performance liquid chromatography (HPLC). During this time, the animals were fasted. And Cmax (maximum plasma concentration), AUC (0-
9h, proportionality constant of the amount of aspirin absorbed), MRT
(Average residence time in the body) was measured. Table 3 shows the results. Tmax (time to reach maximum plasma concentration)
Was read from each blood collection time measurement.
【００３１】[0031]
【表３】 [Table 3]
【００３２】〔比較例〕前記キトサンの代わりに、その
構成単位であるグルコサミンの塩酸塩を使用した以外は
実施例２と同様の操作を行い、溶解性状を観察した。そ
の結果を表４に示す。Comparative Example The same operation as in Example 2 was carried out except that the glucosamine hydrochloride as a constituent unit was used instead of the chitosan, and the solubility was observed. Table 4 shows the results.
【００３３】[0033]
【表４】 [Table 4]
【００３４】[0034]
【発明の効果】以上のように、請求項１の発明によれ
ば、芳香族カルボン酸類に所定量のキトサンを添加、混
合しているので、この水溶性化組成物を水に添加して所
定時間攪拌すれば、単独では水に対してほとんど溶解し
なかった芳香族カルボン酸類をより高濃度で溶解させる
ことができ、その溶解度を向上できるという利点があ
る。そのため、前記芳香族カルボン酸類を内用薬として
使用する場合等には、前記水溶性化組成物を水に溶解さ
せれば十分な量の芳香族カルボン酸類が溶解していると
共に、水溶液として服用できるので、服用の簡便化や吸
収率の増加を図ることができる。また、水溶液として服
用した場合には、体内滞留時間が長くて徐放性があると
いう利点がある。更に、芳香族カルボン酸類とキトサン
とを混合した水溶性化組成物をあらかじめ調製しておけ
ば、これを必要に応じて水に溶解させるだけであるの
で、便利であるという利点がある。As described above, according to the first aspect of the present invention, a predetermined amount of chitosan is added to and mixed with an aromatic carboxylic acid. By stirring for a long time, aromatic carboxylic acids which were hardly dissolved in water alone can be dissolved at a higher concentration, and there is an advantage that the solubility can be improved. Therefore, when the aromatic carboxylic acid is used as an internal medicine, a sufficient amount of the aromatic carboxylic acid is dissolved if the water-solubilizing composition is dissolved in water, and the solution is taken as an aqueous solution. Therefore, simplification of taking and an increase in absorption rate can be achieved. In addition, when taken as an aqueous solution, there is the advantage that the residence time in the body is long and sustained release is achieved. Further, if a water-solubilizing composition in which an aromatic carboxylic acid and chitosan are mixed is prepared in advance, it is convenient to simply dissolve the composition in water as needed.
【００３５】請求項２の発明によれば、前記キトサンの
添加量が、前記芳香族カルボン酸類の重量の１．３倍以
下であるので、前記水溶性化組成物が水に溶解し易いと
いう利点がある。According to the second aspect of the present invention, since the amount of the chitosan added is 1.3 times or less the weight of the aromatic carboxylic acids, the water-solubilizing composition is easily dissolved in water. There is.
【００３６】請求項３の発明によれば、芳香族カルボン
酸類に加えてキトサンを水に溶解させているので、単独
の場合と比較してより高濃度の芳香族カルボン酸類が溶
解しているという利点がある。そのため、この溶解度向
上化水溶液をあらかじめ調製しておけば、前記水溶性化
組成物等を溶解させる手間を省けると共に、内用薬等と
してそのまますぐに利用できるという利点がある。According to the third aspect of the present invention, since chitosan is dissolved in water in addition to aromatic carboxylic acids, a higher concentration of aromatic carboxylic acids is dissolved as compared with the case where chitosan is used alone. There are advantages. Therefore, preparing this aqueous solution with improved solubility in advance has the advantage that the time and effort for dissolving the water-solubilizing composition and the like can be omitted and that the composition can be used immediately as an internal medicine or the like.
【００３７】請求項４の発明によれば、前記芳香族カル
ボン酸類の濃度が３．２ｇ／ｄＬ以下で、且つ、前記キ
トサンの濃度がこの芳香族カルボン酸類の濃度の１．３
倍以下であるので、芳香族カルボン酸類の溶け残りがほ
とんど又は全くないという利点がある。According to the fourth aspect of the present invention, the concentration of the aromatic carboxylic acid is not more than 3.2 g / dL, and the concentration of the chitosan is 1.3 of the concentration of the aromatic carboxylic acid.
Since it is twice or less, there is an advantage that little or no residual aromatic carboxylic acid remains.
【図１】キトサン−アスピリン水溶液の乾燥物（サンプ
ルａ）の赤外吸収スペクトルチャート。FIG. 1 is an infrared absorption spectrum chart of a dried product of chitosan-aspirin aqueous solution (sample a).
【図２】キトサンとアスピリンの混合物（サンプルｂ）
の赤外吸収スペクトルチャート。FIG. 2 Mixture of chitosan and aspirin (sample b)
Infrared absorption spectrum chart of FIG.
【図３】キトサン−アスピリン水溶液の乾燥物（サンプ
ルａ）と、キトサンとアスピリンの混合物（サンプル
ｂ）の両方の赤外吸収スペクトルを表示したチャート。FIG. 3 is a chart showing infrared absorption spectra of both a dried product of chitosan-aspirin aqueous solution (sample a) and a mixture of chitosan and aspirin (sample b).
【図４】キトサンの赤外吸収スペクトルチャート。FIG. 4 is an infrared absorption spectrum chart of chitosan.
【図５】アスピリンの赤外吸収スペクトルチャート。FIG. 5 is an infrared absorption spectrum chart of aspirin.
フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ｃ０７Ｃ 65/03 Ｃ０７Ｃ 65/03 Ｃ 67/62 67/62 69/157 69/157 227/44 227/44 229/60 229/60 Continued on the front page (51) Int.Cl. 6 Identification code FI C07C 65/03 C07C 65/03 C 67/62 67/62 69/157 69/157 227/44 227/44 229/60 229/60
Claims (4)
を添加、混合したことを特徴とする芳香族カルボン酸類
の水溶性化組成物。1. A water-soluble aromatic carboxylic acid composition comprising a predetermined amount of chitosan added to and mixed with an aromatic carboxylic acid.
ルボン酸類の重量の１．３倍以下であることを特徴とす
る請求項１記載の芳香族カルボン酸類の水溶性化組成
物。2. The water-soluble aromatic carboxylic acid composition according to claim 1, wherein the amount of the chitosan added is 1.3 times or less the weight of the aromatic carboxylic acid.
それぞれ所定濃度で溶解させたことを特徴とする芳香族
カルボン酸類の溶解度向上化水溶液。3. An aqueous solution for improving the solubility of aromatic carboxylic acids, wherein an aromatic carboxylic acid and chitosan are dissolved at predetermined concentrations in water.
ｇ／ｄＬ以下で、且つ、前記キトサンの濃度がこの芳香
族カルボン酸類の濃度の１．３倍以下であることを特徴
とする請求項３記載の芳香族カルボン酸類の溶解度向上
化水溶液。4. The concentration of the aromatic carboxylic acid is 3.2.
The aqueous solution for improving the solubility of aromatic carboxylic acids according to claim 3, wherein the concentration of the chitosan is not more than g / dL and the concentration of the chitosan is not more than 1.3 times the concentration of the aromatic carboxylic acids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP02080098A JP4126405B2 (en) | 1998-02-02 | 1998-02-02 | Aqueous solution with improved solubility of aromatic carboxylic acids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP02080098A JP4126405B2 (en) | 1998-02-02 | 1998-02-02 | Aqueous solution with improved solubility of aromatic carboxylic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11222457A true JPH11222457A (en) | 1999-08-17 |
| JP4126405B2 JP4126405B2 (en) | 2008-07-30 |
Family
ID=12037144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP02080098A Expired - Fee Related JP4126405B2 (en) | 1998-02-02 | 1998-02-02 | Aqueous solution with improved solubility of aromatic carboxylic acids |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4126405B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101591470B1 (en) * | 2014-11-19 | 2016-02-03 | 제너럴바이오(주) | A composition for chitosan solution thereof |
| JP2019520377A (en) * | 2016-06-28 | 2019-07-18 | アサメディック アクティーゼルスカブＡｓａｍｅｄｉｃ Ａｓ | Two-component composition |
| US11844806B2 (en) | 2017-12-22 | 2023-12-19 | Asamedic As | Compositions comprising acetylsalicylic acid and a phosphate salt |
| US11850253B2 (en) | 2017-12-22 | 2023-12-26 | Asamedic As | Two component compositions |
-
1998
- 1998-02-02 JP JP02080098A patent/JP4126405B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101591470B1 (en) * | 2014-11-19 | 2016-02-03 | 제너럴바이오(주) | A composition for chitosan solution thereof |
| JP2019520377A (en) * | 2016-06-28 | 2019-07-18 | アサメディック アクティーゼルスカブＡｓａｍｅｄｉｃ Ａｓ | Two-component composition |
| US11918554B2 (en) | 2016-06-28 | 2024-03-05 | Asamedic As | Two-component composition |
| US11844806B2 (en) | 2017-12-22 | 2023-12-19 | Asamedic As | Compositions comprising acetylsalicylic acid and a phosphate salt |
| US11850253B2 (en) | 2017-12-22 | 2023-12-26 | Asamedic As | Two component compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4126405B2 (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1496866B1 (en) | Process for preparing tannate liquid and semi-solid dosage forms | |
| US4859704A (en) | Water soluble ibuprofen compositions and methods of making them | |
| CA2214399C (en) | Soft gelatin capsule with a gelatin shell comprising xanthine derivative | |
| JP2002537317A (en) | Compositions and methods for improved delivery of hydrophobic therapeutic agents | |
| UA72541C2 (en) | A pharmaceutical composition containing benzamide derivative | |
| JPH07252144A (en) | Pharmaceutical composition | |
| WO2008133901A1 (en) | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins | |
| CN100518726C (en) | Pharmaceutical solutions of modafinil compounds | |
| CN105597103A (en) | Solution for spray drying comprising hypromellose acetate succinate and method for producing solid dispersion | |
| PT91682B (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHOPOSIDO | |
| JP4126405B2 (en) | Aqueous solution with improved solubility of aromatic carboxylic acids | |
| CN101541324B (en) | Pharmaceutical composition | |
| JP7532341B2 (en) | Injectable sustained-release antibiotic formulation | |
| WO1995004551A1 (en) | Percutaneously absorbable preparation | |
| PT571973E (en) | DELAYED LIBERTACAO SODIUM VALPROATE TABLETS | |
| EP0386023A1 (en) | Sustained-release nifedipine formulation | |
| AU2002223091A1 (en) | Dermatological formulations containing clindamycin and a zinc-salt | |
| WO2002043739A2 (en) | Dermatological formulations containing clindamycin and a zinc-salt | |
| JPH0840880A (en) | Medicine on basis of ketoprofen in soft gelatin capsule medicine and its preparation | |
| RU2084226C1 (en) | Composition exhibiting antitumor action | |
| CN101142186A (en) | Solid lercanidipine free base | |
| EP0028336B1 (en) | Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions | |
| JPH1171269A (en) | Oral liquid pharmaceutical preparation | |
| CN106511364A (en) | Slow-release azithromycin ion exchange resin compound and application thereof | |
| JPH05306225A (en) | Prolonged action pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071227 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080325 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080424 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110523 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140523 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |